bluebird bio
Biotechnology ResearchView the employees at
bluebird bio-
Marc d'Anjou Sr. Director, Regulatory CMC at bluebird bio
-
Cambridge, Massachusetts, United States
-
Rising Star
Cindy Stockdale Head, Field Market Access-
United States
-
Top 10%
Aradhana Devi,MBA Staff Accountant I I Finance and Accounting I Bluebird Bio-
Greater Boston
-
Top 10%
Qing (Carina) Yu Scientist I at bluebird bio-
Boston, Massachusetts, United States
-
Rising Star
Daniel Hyde Senior Associate Scientist I at bluebird bio-
Cambridge, Massachusetts, United States
-
Rising Star
Overview
bluebird bio is pursuing curative gene therapies to give patients and their families more bluebird days. With a dedicated focus on severe genetic diseases, bluebird has industry-leading programs for sickle cell disease, β-thalassemia and cerebral adrenoleukodystrophy and is advancing research to apply new technologies to these and other diseases. We custom design each of our therapies to address the underlying cause of disease and have developed in-depth and effective analytical methods to understand the safety of our lentiviral vector technologies and drive the field of gene therapy forward. Founded in 2010, bluebird has the largest and deepest ex-vivo gene therapy data set in the world—setting the standard for the industry. Today, bluebird continues to forge new paths, combining our real-world experience with a deep commitment to patient communities and a people-centric culture that attracts and grows a diverse flock of dedicated birds. Community guidelines: http://bit.ly/bbbGuidelines
-